Abstract
A growing share of the pharmaceutical development pipeline is occupied by macromolecule drugs, which are primarily administered by injection. Despite decades of attempts, non-invasive delivery of macromolecules has seen only a few success stories. Potential benefits of non-invasive administration include better patient acceptance and adherence and potentially better efficacy and safety. Greater inter-disciplinary dialogue and collaboration are integral to realizing these benefits.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Moroz E, Matoori S, Leroux JC. Oral delivery of macromolecular drugs: where we are after almost 100years of attempts. Adv Drug Deliv Rev. 2016;101:108–21.
Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov. 2003;2(4):289–95.
Butler JM, Dressman JB. The developability classification system: application of biopharmaceutics concepts to formulation development. J Pharm Sci. 2010;99(12):4940–54.
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1–3):3–26.
Acknowledgments and Disclosures
RS and CS are employees of Catalent Pharma Solutions.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Savla, R., Mrsny, R.J., Park, K. et al. Insights and Lessons from a Scientific Conference on Non-Invasive Delivery of Macromolecules. Pharm Res 34, 1149–1151 (2017). https://doi.org/10.1007/s11095-017-2156-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-017-2156-9